No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
THTX Theratechnologies
- 1.5412
- -0.0188-1.21%
Trading Jul 22 12:05 ET
70.86MMarket Cap-11855P/E (TTM)
1.5700High1.5300Low32.90KVolume1.5900Open1.5600Pre Close50.82KTurnover0.12%Turnover RatioLossP/E (Static)45.98MShares3.290052wk High-3.05P/B42.00MFloat Cap0.880052wk Low--Dividend TTM27.25MShs Float17.8400Historical High--Div YieldTTM2.56%Amplitude0.8800Historical Low1.5440Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Theratechnologies Second Quarter 2024 Earnings: Beats Expectations
Theratechnologies: Strong Q2 Performance and Positive Outlook Justify Buy Rating
JonesTrading Maintains Theratechnologies(THTX.US) With Buy Rating, Maintains Target Price $3
JonesTrading analyst Justin Walsh maintains $Theratechnologies(THTX.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 37.0%
Earnings Call Summary | Theratechnologies(THTX.US) Q2 2024 Earnings Conference
The following is a summary of the Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript:Financial Performance:Theratechnologies reported second quarter revenue at $22 million, a 25% year-
Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript
Theratechnologies Inc. (THTX) Q2 2024 Earnings Call Transcript
HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars
On Wednesday, Theratechnologies Inc (NASDAQ:THTX) reported second-quarter 2024 sales of $22.02 million, up 25.5% year over year, beating the consensus of $21.71 million.For the second quarter, net
Comments
$Theratechnologies(THTX.US$
NEWS
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a uni...
NEWS
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a uni...
1
$Theratechnologies(THTX.US$
NEWS
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
05/02/2024 - 04:30 AM
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the...
NEWS
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
05/02/2024 - 04:30 AM
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing
MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the...
$Theratechnologies(THTX.US$ NASDAQ: THTX) announced moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer.
1
📌Last week’s PDUFAs:
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
12
1
$Theratechnologies(THTX.US$ Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
4 MINUTES AGO, 7:00 AM EST![]()
4 MINUTES AGO, 7:00 AM EST
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg